Log in

Relevant bibliographies by topics / Pancreatic neuroendocrine tumour / Journal articles

To see the other types of publications on this topic, follow the link: Pancreatic neuroendocrine tumour.

Journal articles on the topic 'Pancreatic neuroendocrine tumour'

Author: Grafiati

Published: 11 March 2023

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Pancreatic neuroendocrine tumour.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Durga, Kharidehal, Nandam Mohan Rao, and Byna Syam Sundara Rao. "Mixed Neuroendocrine - Non-Neuroendocrine Neoplasm (MiNEN) - A Rare Heterogenous Malignancy of the Pancreas." International Journal of Research and Review 10, no. 6 (2023): 306–10. http://dx.doi.org/10.52403/ijrr.20230637.

Full text

Abstract:

Introduction: Pancreatic mixed neuroendocrine non-neuroendocrine neoplasms are extremely rare tumours accounting for 0.5% of all the pancreatic malignancies and 5% of all pancreatic neuroendocrine neoplasms. These tumors are rarely diagnosed preoperatively and they have a poor prognosis. Pancreatic MiNEN is characterized by 2 malignant lesions adenocarcinoma and Neuroendocrine tumour with each constituent involving more than 30% of the tumour. We report a case of 57yr old male with dullaching abdominal pain radiating to back. CA 19-9 was mildly elevated. Other laboratory tests are within norma

APA, Harvard, Vancouver, ISO, and other styles

2

Maslin, D., B. Challis, and H. Simpson. "Metastatic pancreatic neuroendocrine tumour." QJM 109, no. 5 (2016): 355. http://dx.doi.org/10.1093/qjmed/hcw036.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Mormul, Agata, Emilia Włoszek, Julia Nowoszewska, et al. "Rare Non-Neuroendocrine Pancreatic Tumours." Cancers 15, no. 8 (2023): 2216. http://dx.doi.org/10.3390/cancers15082216.

Full text

Abstract:

The most common tumour of the pancreas is ductal adenocarcinoma (PDAC). It remains one of the most lethal non-neuroendocrine solid tumours despite the use of a multi-approach strategy. Other, less-common neoplasms, which are responsible for 15% of pancreatic lesions, differ in treatment and prognosis. Due to the low incidence rate, there is a lack of information about the rarest pancreatic tumours. In this review, we described six rare pancreatic tumours: intraductal papillary mucinous neoplasm (IPMN), mucinous cystadenoma (MCN), serous cystic neoplasm (SCN), acinar cell carcinoma (ACC), solid

APA, Harvard, Vancouver, ISO, and other styles

4

Ferrel, Benjamin, Jan Franko, and May C. Tee. "Rare case of pancreatic neuroendocrine tumour presenting as paraneoplastic hypercalcaemia." BMJ Case Reports 14, no. 4 (2021): e240786. http://dx.doi.org/10.1136/bcr-2020-240786.

Full text

Abstract:

An asymptomatic 68-year-old woman who presented with an isolated hypercalcaemia was diagnosed with a rare, previously unsuspected parathyroid hormone-related peptide (PTHrP)-producing pancreatic neuroendocrine tumour. She underwent an extensive operation including vascular resection and reconstruction, resulting in successful removal of the tumour with negative margins. Medical and surgical management of pancreatic neuroendocrine tumours and PTHrP-mediated paraneoplastic hypercalcaemia is discussed.

APA, Harvard, Vancouver, ISO, and other styles

5

Weerasuriya, Scott, Kieran Palmer, Stephen Gregory, Benjamin C. Whitelaw, Elisa Gonzalez, and Rajaventhan Srirajaskanthan. "Mesenteric Variceal Haemorrhage and Ectopic Cushing’s Syndrome as Presenting Features of a Pancreatic Neuroendocrine Tumour Recurrence." Case Reports in Gastroenterology 15, no. 3 (2021): 919–26. http://dx.doi.org/10.1159/000518021.

Full text

Abstract:

Pancreatic neuroendocrine tumours can have varied and complex presentations. Whilst hormone hypersecretion often induces characteristic clinical syndromes, non-specific symptoms may arise due to localized tumour effects. Malignant invasion of local vasculature is an increasingly recognized complication of these neoplasms and can be associated with significant morbidity. Herein, we present the case of a 47-year-old male with a recurrence of a pancreatic neuroendocrine tumour who presented with unusual upper gastrointestinal bleeding. The tumour had recurred within the superior mesenteric vein,

APA, Harvard, Vancouver, ISO, and other styles

6

Kann, P. H., E. Balakina, D. Ivan, et al. "Natural course of small, asymptomatic neuroendocrine pancreatic tumours in multiple endocrine neoplasia type 1: an endoscopic ultrasound imaging study." Endocrine-Related Cancer 13, no. 4 (2006): 1195–202. http://dx.doi.org/10.1677/erc.1.01220.

Full text

Abstract:

Endoscopic ultrasound (EUS) enables detection and localization of pancreatic neuroendocrine tumours. Even small tumours down to a diameter of 1–2 mm can be visualized. Since such small tumours usually cannot be detected by computed tomography (ct), magnetic resonance imaging (mri) and somatostatin receptor scintigraphy (srs), and experience with EUS imaging is limited, there is no clear evidence for clinical management in multiple endocrine neoplasia type 1 (MEN1). Knowledge about the natural course of growth and metastatic distribution is mandatory to come to appropriate clinical decisions an

APA, Harvard, Vancouver, ISO, and other styles

7

Laccourreye, Ollivier, Eric Chabardes, Gregory Weinstein, Francoise Carnot, Daniel Brasnu, and Henri Laccourreye. "Synchronous arytenoid and pancreatic neuroendocrine carcinoma." Journal of Laryngology & Otology 105, no. 5 (1991): 373–75. http://dx.doi.org/10.1017/s0022215100116044.

Full text

Abstract:

AbstractNeuroendocrine laryngeal carcinoid tumours are uncommon. The supraglottis is the main location of these tumours. Eighty-one cases have been reported in the world literature. We present the first case of a synchronous laryngeal and pancreatic neuroendocrine tumour.

APA, Harvard, Vancouver, ISO, and other styles

8

Venugopal, Abhirami, Agnes Michalczyk, Mustafa Khasraw, and M. Leigh Ackland. "EMT Molecular Signatures of Pancreatic Neuroendocrine Neoplasms." International Journal of Molecular Sciences 23, no. 21 (2022): 13645. http://dx.doi.org/10.3390/ijms232113645.

Full text

Abstract:

Neuroendocrine neoplasms (NENs) are relatively rare neoplasms occurring predominantly in the gastrointestinal tract and pancreas. Their heterogeneity poses challenges for diagnosis and treatment. There is a paucity of markers for characterisation of NEN tumours. For routine diagnosis, immunohistochemistry of the NEN-specific markers CgA and synaptophysin and the proliferation marker Ki-67 are used. These parameters, however, are qualitative and lack the capacity to fully define the tumour phenotype. Molecules of epithelial–mesenchymal transition (EMT) are potential candidates for improved tumo

APA, Harvard, Vancouver, ISO, and other styles

9

Bertani, Helga, Alessandro Messerotti, Fabrizio Di Benedetto, et al. "Unusual Paraneoplastic Syndrome Accompanies Neuroendocrine Tumours of the Pancreas." Case Reports in Medicine 2011 (2011): 1–4. http://dx.doi.org/10.1155/2011/309149.

Full text

Abstract:

Neuroendocrine tumours comprise a small percentage of pancreatic neoplasia (10%) (1). Diagnosis of neuroendocrine tumours is difficult, especially if the tumours are small and nonfunctional. CT scans, MRI, and nuclear scans are sufficiently sensitive assessment tools for tumours with diameters of at least 2 cm; otherwise, the sensitivity and specificity of these techniques is less than 50% (2). Myasthenia gravis (MG) is a heterogeneous neuromuscular junction disorder that is primarily caused when antibodies form against the acetylcholine receptors (Ab-AchR). MG can develop in conjunction with

APA, Harvard, Vancouver, ISO, and other styles

10

Lines, K. E., R. P. Vas Nunes, M. Frost, C. J. Yates, M. Stevenson, and R. V. Thakker. "A MEN1 pancreatic neuroendocrine tumour mouse model under temporal control." Endocrine Connections 6, no. 4 (2017): 232–42. http://dx.doi.org/10.1530/ec-17-0040.

Full text

Abstract:

Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominant disorder characterised by occurrence of parathyroid tumours and neuroendocrine tumours (NETs) of the pancreatic islets and anterior pituitary. The MEN1 gene, encoding menin, is a tumour suppressor, but its precise role in initiating in vivo tumourigenesis remains to be elucidated. The availability of a temporally controlled conditional MEN1 mouse model would greatly facilitate the study of such early tumourigenic events, and overcome the limitations of other MEN1 knockout models, in which menin is lost from conception or tumou

APA, Harvard, Vancouver, ISO, and other styles

11

Varshney, Bharti, Jyotsna Naresh Bharti, Vaibhav Kumar Varshney, and Taruna Yadav. "Mixed neuroendocrine-non-neuroendocrine neoplasms (MiNEN) of pancreas: a rare entity—worth to note." BMJ Case Reports 13, no. 4 (2020): e234855. http://dx.doi.org/10.1136/bcr-2020-234855.

Full text

Abstract:

Mixed adenocarcinoma with neuroendocrine tumour of pancreas has been reported infrequently and consists of both epithelial and neuroendocrine component. We encountered an 81-year-old male patient who presented with clinical features of painful progressive jaundice for 1 month. Contrast-enhanced CT abdomen reported a mass in the pancreatic head with dilated common bile duct and pancreatic duct. He underwent pancreatoduodenectomy and histopathological examination revealed two different tumours: ductal adenocarcinoma admixed with neuroendocrine tumour of pancreas. He received adjuvant chemotherap

APA, Harvard, Vancouver, ISO, and other styles

12

Varshney, Vaibhav Kumar, Raghav Nayar, Taruna Yadav, and Sudeep Khera. "Duodenal gastrointestinal stromal tumour imitating as pancreatic head tumour." BMJ Case Reports 15, no. 3 (2022): e248828. http://dx.doi.org/10.1136/bcr-2022-248828.

Full text

Abstract:

Duodenal gastrointestinal stromal tumours (D-GISTs) are a rare disease. It may arise commonly from the second or third part of the duodenum and can be erroneously diagnosed as a pancreatic head tumour due to proximity and morphology on imaging studies. We present a case of a 60-year-old woman who presented with abdominal pain and was diagnosed as a case of pancreatic neuroendocrine tumour on radiologic imaging and granulomatous lesion on aspiration cytology. A ~5×3 cm mass was noted in the pancreatic head on laparotomy, and pancreatoduodenectomy was performed. Histopathology reported an exophy

APA, Harvard, Vancouver, ISO, and other styles

13

Wang, C. Y., J. C. Lin, Y. F. Li, and C. W. Yang. "Alpha-fetoprotein producing pancreatic neuroendocrine tumour." QJM: An International Journal of Medicine 113, no. 8 (2020): 565–66. http://dx.doi.org/10.1093/qjmed/hcaa018.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Rico, Karen, Suzann Duan, Ritu L. Pandey, et al. "Genome analysis identifies differences in the transcriptional targets of duodenal versus pancreatic neuroendocrine tumours." BMJ Open Gastroenterology 8, no. 1 (2021): e000765. http://dx.doi.org/10.1136/bmjgast-2021-000765.

Full text

Abstract:

ObjectiveGastroenteropancreatic neuroendocrine tumours (GEP-NETs) encompass a diverse group of neoplasms that vary in their secretory products and in their location within the gastrointestinal tract. Their prevalence in the USA is increasing among all adult age groups.AimTo identify the possible derivation of GEP-NETs using genome-wide analyses to distinguish small intestinal neuroendocrine tumours, specifically duodenal gastrinomas (DGASTs), from pancreatic neuroendocrine tumours.DesignWhole exome sequencing and RNA-sequencing were performed on surgically resected GEP-NETs (discovery cohort).

APA, Harvard, Vancouver, ISO, and other styles

15

Zierhut, B., K. Mechtler, W. Gartner, et al. "Heat shock protein 70 (Hsp70) subtype expression in neuroendocrine tissue and identification of a neuroendocrine tumour-specific Hsp70 truncation." Endocrine-related cancer 11, no. 2 (2004): 377–89. http://dx.doi.org/10.1677/erc.0.0110377.

Full text

Abstract:

In order to identify neuroendocrine tumour-specific protein expression, we generated monoclonal antibodies (mAbs) with a tumour-related reaction pattern using a human insulinoma as immunogen. One of the generated mAbs (mAb 1D4) exhibited striking immunoreactivity against various neuroendocrine tumours without staining pancreatic islets of Langerhans. Furthermore, mAb 1D4 immunostained a characteristic subtype of hypothalamic neurones. Using two-dimensional (2-D) gel electrophoresis, mAb 1D4 immunoblotting and mass spectrometry, heat shock protein 70 (Hsp70) isoforms were identified as the mAb

APA, Harvard, Vancouver, ISO, and other styles

16

Gunda, Deepika, Jack Naughton, Sean Gregory Stevens, and Marcos V. Perini. "Castleman’s disease masquerading as pancreatic neuroendocrine tumour." BMJ Case Reports 14, no. 6 (2021): e242597. http://dx.doi.org/10.1136/bcr-2021-242597.

Full text

Abstract:

Castleman’s disease (CD) is a rare lymphoproliferative disorder. This case report, to the best of our knowledge, is the first report of CD simulating a pancreatic neuroendocrine tumour . The patient was a 58-year-old woman who initially presented with bilateral iritis and underwent investigation for possible systemic rheumatological disease. CT of the chest demonstrated an incidental finding of a well-demarcated retropancreatic mass. As the mass was found to enhance on DOTATATE (tetraazacyclododecanetetraacetic acid-DPhe1-Tyr3-octreotate) positron emission tomography, a diagnosis of pancreatic

APA, Harvard, Vancouver, ISO, and other styles

17

M, Sneha, Swarna Sri, and Anunayi J. "Pancreatic Neuroendocrine Tumour- An Interesting Case Report." Journal of Evolution of Medical and Dental Sciences 9, no. 19 (2020): 1575–78. http://dx.doi.org/10.14260/jemds/2020/344.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Cerezal Gómez, G., T. Savescu, C. López Martín, et al. "Unicentric Castleman disease mimicking pancreatic neuroendocrine tumour." Pancreatology 23, no. 7 (2023): e12. http://dx.doi.org/10.1016/j.pan.2023.09.115.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Moya-Valverde, E., J. Núñez-Otero, M. Martin-Matas, et al. "Undescribed metastases within a pancreatic neuroendocrine tumour." Endoscopy 57, S 02 (2025): S359. https://doi.org/10.1055/s-0045-1805896.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Bartz, C., C. Ziske, B. Wiedenmann, and K. Moelling. "p53 tumour suppressor gene expression in pancreatic neuroendocrine tumour cells." Gut 38, no. 3 (1996): 403–9. http://dx.doi.org/10.1136/gut.38.3.403.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Tremblay, Catherine, and Isabelle Marcil. "Necrolytic Migratory Erythema: A Forgotten Paraneoplastic Condition." Journal of Cutaneous Medicine and Surgery 21, no. 6 (2017): 559–61. http://dx.doi.org/10.1177/1203475417719051.

Full text

Abstract:

Background: Necrolytic migratory erythema (NME) is most commonly a paraneoplastic condition. It is the dermatologic manifestation classically associated with glucagonoma pancreatic neuroendocrine tumour. Glucagonoma syndrome has been defined by the constellation of secreting tumour associated with overproduction by the α-cells in the pancreatic islets of Langerhans, abnormally elevated blood level of glucagon, and skin findings of NME. Objective: Although rare, all dermatologists must know and recognise NME promptly to request useful investigations for the diagnosis of this characteristic neur

APA, Harvard, Vancouver, ISO, and other styles

22

O'Dowling, Aidan, Michelle Fox, Micheal Hanly, et al. "Impact of pancreatic tumour biomechanics on diagnosis and post-operative complications." Journal of Clinical Oncology 43, no. 4_suppl (2025): 756. https://doi.org/10.1200/jco.2025.43.4_suppl.756.

Full text

Abstract:

756 Background: Around 600 people are diagnosed with pancreatic cancer in Ireland each year, with 90% of these having pancreatic ductal adenocarcinoma (PDAC). Five-year survival for PDAC is around 10%. PDAC upregulates stromal collagen formation which contributes to tissue stiffness. Stiffer pancreatic tumours have worse oncological outcomes due to faster progression and increased chemoresistance. Softer pancreata, conversely, are more likely to develop post-operative pancreatic fistulae (POPF), a significant post-pancreatectomy complication. While incorporated in risk scores, softness is curr

APA, Harvard, Vancouver, ISO, and other styles

23

Zaborowski, Alexandra, Siun M. Walsh, Narayanasamy Ravi, and John V. Reynolds. "Pancreatic Aetiology for Massive Upper Gastrointestinal Haemorrhage in Pregnancy." Case Reports in Surgery 2016 (2016): 1–4. http://dx.doi.org/10.1155/2016/5491851.

Full text

Abstract:

We present herein what we believe is the first reported case of massive upper gastrointestinal bleeding in pregnancy due to a pancreatic neuroendocrine tumour causing left sided portal hypertension. A 37-year-old 27-week pregnant female presented with massive haematemesis and melaena requiring transfusion of 10 units of red cell concentrate. Gastric varices were evident at endoscopy. An MRI revealed a large mass infiltrating the pancreatic tail and spleen with massive upper abdominal varix formation secondary to splenic vein invasion. A caesarean section was performed, followed by a radical en

APA, Harvard, Vancouver, ISO, and other styles

24

Lamarca, Clouston, Barriuso, et al. "Follow-Up Recommendations after Curative Resection of Well-Differentiated Neuroendocrine Tumours: Review of Current Evidence and Clinical Practice." Journal of Clinical Medicine 8, no. 10 (2019): 1630. http://dx.doi.org/10.3390/jcm8101630.

Full text

Abstract:

The incidence of neuroendocrine neoplasms (NENs) is increasing, especially for patients with early stages and grade 1 tumours. Current evidence also shows increased prevalence, probably reflecting earlier stage diagnosis and improvement of treatment options. Definition of adequate postsurgical follow-up for NENs is a current challenge. There are limited guidelines, and heterogeneity in adherence to those available is notable. Unfortunately, the population of patients at greatest risk of recurrence has not been defined clearly. Some studies support that for patients with pancreatic neuroendocri

APA, Harvard, Vancouver, ISO, and other styles

25

Pardillos Tomé, Ana, Eduardo Bajador Andreu, Ana Comín Orce, and Francisco Marcilla Córdoba. "Familial adenomatous polyposis associated with pancreatic neuroendocrine tumour." Gastroenterología y Hepatología (English Edition) 44, no. 2 (2021): 130–31. http://dx.doi.org/10.1016/j.gastre.2020.05.013.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Nowowiejska, Julia, Anna Baran, and Iwona Flisiak. "Folliculotropic mycosis fungoides coexisting with pancreatic neuroendocrine tumour." Dermatology Review 105, no. 6 (2018): 746–52. http://dx.doi.org/10.5114/dr.2018.80844.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Halappanavar, Anup, and Rajeev Pakhetra. "An unusual presentation of pancreatic neuroendocrine tumour (PNET)." Clinical Medicine 19, Suppl 3 (2019): 7–8. http://dx.doi.org/10.7861/clinmedicine.19-3-s7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Halappanavar, Anup, and Rajeev Pakhetra. "An unusual presentation of pancreatic neuroendocrine tumour (PNET)." Clinical Medicine 19, Suppl 3 (2019): s7—s8. http://dx.doi.org/10.7861/clinmedicine.19-3s-s7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Ueno, Tatsuya, Masaki Munakata, and Masahiko Tomiyama. "Unilateral Ptosis Caused by Pancreatic Neuroendocrine Tumour Metastases." Internal Medicine 58, no. 1 (2019): 151–52. http://dx.doi.org/10.2169/internalmedicine.1498-18.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Clift, Ashley Kieran, Mark Kidd, Lisa Bodei, et al. "Neuroendocrine Neoplasms of the Small Bowel and Pancreas." Neuroendocrinology 110, no. 6 (2019): 444–76. http://dx.doi.org/10.1159/000503721.

Full text

Abstract:

The traditionally promulgated perspectives of neuroendocrine neoplasms (NEN) as rare, indolent tumours are blunt and have been outdated for the last 2 decades. Clear increments in their incidence over the past decades render them increasingly clinically relevant, and at initial diagnosis many present with nodal and/or distant metastases (notably hepatic). The molecular pathogenesis of these tumours is increasingly yet incompletely understood. Those arising from the small bowel (SB) or pancreas typically occur sporadically; the latter may occur within the context of hereditary tumour predisposi

APA, Harvard, Vancouver, ISO, and other styles

31

Yang, Zhizhou, Jorge G. Zarate Rodriguez, Haley Beck, Kathleen Byrnes, Nikolaos A. Trikalinos, and Chet W. Hammill. "Acinar cell carcinoma with PRKAR1A and PTEN alterations and paraneoplastic panniculitis." BMJ Case Reports 15, no. 12 (2022): e251400. http://dx.doi.org/10.1136/bcr-2022-251400.

Full text

Abstract:

Pancreatic acinar cell carcinoma is a rare type of pancreatic malignancy, which can be confused with pancreatic neuroendocrine neoplasm. Here, we describe a woman in her 80s who presented with abdominal pain and bilateral lower extremity panniculitis. She underwent surgery for a presumed diagnosis of neuroendocrine tumour with PTEN and PRKAR1A alterations; 19 months, later, a recurrence of her pancreatic malignancy was discovered. The patient underwent repeat resection and this time immunohistochemical staining confirmed the diagnosis of acinar cell carcinoma. Staining for acinar cell carcinom

APA, Harvard, Vancouver, ISO, and other styles

32

Gyorki, DE, NE Clarke, MW Hii, SW Banting, and RJ Cade. "Management of synchronous tumours of the oesophagus and pancreatic head: a novel approach." Annals of The Royal College of Surgeons of England 93, no. 6 (2011): e111-e113. http://dx.doi.org/10.1308/147870811x591675.

Full text

Abstract:

Synchronous tumours of the oesophagus and pancreatic head are very rare. This report describes a unique case of an adenocarcinoma of the distal oesophagus and a neuroendocrine tumour of the pancreatic head diagnosed synchronously but successfully managed metachronously. Initially, the patient underwent an oesophagectomy, with a colonic reconstruction following some months later by pylorus-preserving pancreaticoduodenectomy. A staged resection was performed after a review of the literature suggested increased morbidity with synchronous major abdominal operations.

APA, Harvard, Vancouver, ISO, and other styles

33

Ward J, Jocelyn, Tahir Omer, and Ibrahim M Souar El-Dahab. "Pancreatic Neuroendocrine Tumour as a Cause of Ectopic Cushing’s Syndrome: A Rare Case Report." Annals of Clinical Case Reports 7, no. 1 (2022): 1–3. http://dx.doi.org/10.25107/2474-1655-v7-id2261.

Full text

Abstract:

Pancreatic Neuroendocrine Tumors (pNETs) are rare neoplasms arising from the neuroendocrine islet cells of the pancreas and account for only 1% to 2% of all pancreatic malignancies. These tumors may secrete hormones; however 60% are considered ‘non-functional’ with no evidence of ectopic hormone secretion. Functional pNETs are known to secrete insulin, gastrin, glucagon, vasoactive intestinal peptide or somatostatin. A small number of the cases reported to date of this condition were typically for patients presenting with Cushing syndrome, where the tumor was discovered during investigations f

APA, Harvard, Vancouver, ISO, and other styles

34

Krug, Sebastian, Julia Weissbach, Annika Blank, et al. "CUX1—Transcriptional Master Regulator of Tumor Progression in Pancreatic Neuroendocrine Tumors." Cancers 12, no. 7 (2020): 1957. http://dx.doi.org/10.3390/cancers12071957.

Full text

Abstract:

Recently, we identified the homeodomain transcription factor Cut homeobox 1 (CUX1) as mediator of tumour de-differentiation and metastatic behaviour in human insulinoma patients. In insulinomas, CUX1 enhanced tumour progression by stimulating proliferation and angiogenesis in vitro and in vivo. In patients with non-functional pancreatic neuroendocrine tumours (PanNET), however, the impact of CUX1 remains to be elucidated. Here, we analysed CUX1 expression in two large independent cohorts (n = 43 and n = 141 tissues) of non-functional treatment-naïve and pre-treated PanNET patients, as well as

APA, Harvard, Vancouver, ISO, and other styles

35

Veron Sanchez, Ana, Nuria Santamaria Guinea, Silvia Cayon Somacarrera, Ilias Bennouna, Martina Pezzullo, and Maria Bali. "Rare Solid Pancreatic Lesions on Cross-Sectional Imaging." Diagnostics 13, no. 16 (2023): 2719. http://dx.doi.org/10.3390/diagnostics13162719.

Full text

Abstract:

Several solid lesions can be found within the pancreas mainly arising from the exocrine and endocrine pancreatic tissue. Among all pancreatic malignancies, the most common subtype is pancreatic ductal adenocarcinoma (PDAC), to a point that pancreatic cancer and PDAC are used interchangeably. But, in addition to PDAC, and to the other most common and well-known solid lesions, either related to benign conditions, such as pancreatitis, or not so benign, such as pancreatic neuroendocrine neoplasms (pNENs), there are solid pancreatic lesions considered rare due to their low incidence. These lesions

APA, Harvard, Vancouver, ISO, and other styles

36

Ney, Alexander, Gabriele Canciani, J. Justin Hsuan, and Stephen P. Pereira. "Modelling Pancreatic Neuroendocrine Cancer: From Bench Side to Clinic." Cancers 12, no. 11 (2020): 3170. http://dx.doi.org/10.3390/cancers12113170.

Full text

Abstract:

Pancreatic neuroendocrine tumours (pNETs) are a heterogeneous group of epithelial tumours with neuroendocrine differentiation. Although rare (incidence of <1 in 100,000), they are the second most common group of pancreatic neoplasms after pancreatic ductal adenocarcinoma (PDAC). pNET incidence is however on the rise and patient outcomes, although variable, have been linked with 5-year survival rates as low as 40%. Improvement of diagnostic and treatment modalities strongly relies on disease models that reconstruct the disease ex vivo. A key constraint in pNET research, however, is the absen

APA, Harvard, Vancouver, ISO, and other styles

37

Jamieson, A., and J. M. C. Connell. "Neuroendocrine Pancreatic Cancer: An Unusual Case of Pancreatitis." Scottish Medical Journal 45, no. 2 (2000): 55–56. http://dx.doi.org/10.1177/003693300004500209.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Lin, Shaojian, Anke Zhang, Xun Zhang, and Zhe Bao Wu. "Treatment of Pituitary and Other Tumours with Cabergoline: New Mechanisms and Potential Broader Applications." Neuroendocrinology 110, no. 6 (2019): 477–88. http://dx.doi.org/10.1159/000504000.

Full text

Abstract:

Cabergoline is a dopamine agonist that has been used as the first-line treatment option for prolactin-secreting pituitary adenomas for several decades. It not only suppresses hormone production from these prolactinomas, but also causes tumour shrinkage. Recent studies revealed some novel mechanisms by which cabergoline suppresses tumour cell proliferation and induces cell death. In this article, we review the most recent findings in cabergoline studies, focusing on its anti-tumour function. These studies suggest the potential broader clinical use of cabergoline in the treatment of other tumour

APA, Harvard, Vancouver, ISO, and other styles

39

Angelico, Roberta, Leandro Siragusa, Cristine Brooke Pathirannehalage Don, et al. "Pancreatic Adeno-MiNEN, a Rare Newly Defined Entity with Challenging Diagnosis and Treatment: A Case Report with Systematic Literature Review and Pooled Analysis." Journal of Clinical Medicine 11, no. 17 (2022): 5021. http://dx.doi.org/10.3390/jcm11175021.

Full text

Abstract:

Mixed neuroendocrine non-neuroendocrine neoplasms (MiNEN) are a peculiar entity that can occur throughout the whole gastrointestinal trait, and pancreatic localization is rare. Their main characteristic is the presence of at least a neuroendocrine and an epithelial component, each accounting for at least 30% of the tumour mass. The presence of epithelial ductal component defines adeno-MiNEN. We report a case of a 59-year-old woman affected by pancreatic adeno-MiNEN with challenging diagnosis and successfully treated. A systematic literature review and pooled analysis was also performed, aiming

APA, Harvard, Vancouver, ISO, and other styles

40

Stridsberg, M., K. Öberg, Q. Li, U. Engström, and G. Lundqvist. "Measurements of chromogranin A, chromogranin B (secretogranin I), chromogranin C (secretogranin II) and pancreastatin in plasma and urine from patients with carcinoid tumours and endocrine pancreatic tumours." Journal of Endocrinology 144, no. 1 (1995): 49–59. http://dx.doi.org/10.1677/joe.0.1440049.

Full text

Abstract:

Abstract Chromogranins and/or secretogranins constitute a family of water-soluble acidic glycoproteins that are present in almost all endocrine, neuroendocrine and neuronal tissue. Antibodies against chromogranins have been widely used for immunohistochemical staining of endocrine tissue and tumours of neuroendocrine origin. Furthermore, measurements of circulating chromogranin A have been used as a reliable marker for neuroendocrine tumour growth. In this study, we describe the development of specific antibodies against chromogranin A, chromogranin B (secretogranin I), chromogranin C (secreto

APA, Harvard, Vancouver, ISO, and other styles

41

Bobrovs, E., J. Pavulans, I. Konrade, R. Laguns, and H. Plaudis. "Patient with multifocal pancreatic insulinoma: a rare presentation of functional pancreatic neuroendocrine neoplasm." General Surgery, no. 2 (November 15, 2023): 62–68. http://dx.doi.org/10.30978/gs-2023-2-62.

Full text

Abstract:

Insulinoma is a type of neuroendocrine tumour with an incidence of 1—4 cases per million. Multiple insulinomas constitute less than 10% of all insulinomas. Surgery is the treatment of choice for insulinoma. The operation can be done with an open or laparoscopic approach, with cure rates ranging from 77% to 100%. Pancreatic resection is recommended for tumours larger than 2 cm in size, while enucleation is advised for lesions smaller than 2cm if the tumour is at least 2—3 mm away from the main pancreatic duct to prevent the formation of a fistula. For better intraoperative localization of lesio

APA, Harvard, Vancouver, ISO, and other styles

42

Gulpinar, Basak, Elif Peker, Cigdem Soydal, Mine Araz, and Atilla Halil Elhan. "Can we differentiate histologic subtypes of neuroendocrine tumour liver metastases at a single phase contrast-enhanced CT—correlation with Ga-68 DOTATATE PET/CT findings." British Journal of Radiology 93, no. 1106 (2020): 20190735. http://dx.doi.org/10.1259/bjr.20190735.

Full text

Abstract:

Objective: To assess the usefulness of a single-phase contrast-enhanced CT to differentiate subtypes of neuroendocrine tumour (NET) liver metastases and to evaluate the correlation between CT features and Ga-68 DOTATATE positron emission tomography/CT (PET/CT) findings. Methods: Between December 2017 and April 2019 patients with liver metastases of neuroendocrine tumours who underwent CT and Ga-68 DOTATATE PET/CT were enrolled in the study. All patients involved in the study had undergone a standardised single-phase contrast-enhanced CT. Whole body PET/CT images were obtained with a combined P

APA, Harvard, Vancouver, ISO, and other styles

43

Predescu, Dragoş. "Pancreatic Neuroendocrine Tumour in Pregnancy - Diagnosis and Treatment Management." Chirurgia 114, no. 5 (2019): 550. http://dx.doi.org/10.21614/chirurgia.114.5.550.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Karanth, Jnanaprakash B., Vishwas Pai, and Kiran Maribashetti. "Pancreatic neuroendocrine tumour—insulinoma masquerading as a psychiatric illness." BMJ Case Reports 15, no. 6 (2022): e249698. http://dx.doi.org/10.1136/bcr-2022-249698.

Full text

Abstract:

A female patient in her early sixties had problems of recurrent syncopal attacks and panic attacks over the last 5 years. She had been initially managed for an anxiety disorder with psychiatric medications. During one of those episodes, she was brought to our hospital in an unconscious state with a low blood sugar level of 43 mg/dL. She was suspected to have a neuroendocrine tumour and diagnosis was established by supervised fasting up to 72 hours and imaging. Her recorded blood sugar during fasting was 37 mg/dL. She underwent surgery and presently remains asymptomatic. Physicians should have

APA, Harvard, Vancouver, ISO, and other styles

45

Cheuk, YY, WK Lo, SK Chan, and CW Wong. "Pancreatic Neuroendocrine Tumour Causing Chronic Diarrhoea: Radiological-Pathological Correlations." Hong Kong Journal of Radiology 17, no. 1 (2014): 45–48. http://dx.doi.org/10.12809/hkjr1412150.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Peixoto, Armando, Pedro Pereira, Susana Lopes, and Guilherme Macedo. "Pancreatic neuroendocrine tumour simulating an intraductal papillary mucinous neoplasm." Digestive and Liver Disease 47, no. 3 (2015): 256. http://dx.doi.org/10.1016/j.dld.2014.10.015.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Rebours, Vinciane, Jacqueline Cordova, Anne Couvelard, et al. "Can pancreatic neuroendocrine tumour biopsy accurately determine pathological characteristics?" Digestive and Liver Disease 47, no. 11 (2015): 973–77. http://dx.doi.org/10.1016/j.dld.2015.06.005.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Guidetti, Elena, Monica Cevenini, Maria Luigia Cipollini, Martina Ferrata, Paola Tomassetti, and Roberto Corinaldesi. "MEN1 syndrome: an anusual case." Clinical Management Issues 6, no. 1S (2015): 23–28. http://dx.doi.org/10.7175/cmi.v6i1s.493.

Full text

Abstract:

Multiple endocrine neoplasia type 1 (MEN1) is a rare autosomal dominant endocrine disorder and is characterised by the concurrent appearance of adenomas of the parathyroid glands, neuroendocrine-enteropancreatic tumours, and pituitary adenomas, as well as other types of less frequent tumours, such as adrenal cortical tumours, carcinoid tumours, lipomas, etc. Two different forms, familial and sporadic, have been described. The gene responsible, MEN1, consists of 10 exons encoding a 610-amino acid protein known as menin. The MEN1 syndrome is caused by inactivating mutations in MEN1 tumour suppre

APA, Harvard, Vancouver, ISO, and other styles

49

Krug, Sebastian, Benjamin Kühnemuth, Heidi Griesmann, et al. "CUX1: a modulator of tumour aggressiveness in pancreatic neuroendocrine neoplasms." Endocrine-Related Cancer 21, no. 6 (2014): 879–90. http://dx.doi.org/10.1530/erc-14-0152.

Full text

Abstract:

Pancreatic neuroendocrine neoplasms (PNENs) constitute a rare tumour entity, and prognosis and treatment options depend on tumour-mediating hallmarks such as angiogenesis, proliferation rate and resistance to apoptosis. The molecular pathways that determine the malignant phenotype are still insufficiently understood and this has limited the use of effective combination therapies in the past. In this study, we aimed to characterise the effect of the oncogenic transcription factor Cut homeobox 1 (CUX1) on proliferation, resistance to apoptosis and angiogenesis in murine and human PNENs. The expr

APA, Harvard, Vancouver, ISO, and other styles

50

Alsadik, Shahad, Siraj Yusuf, and Adil AL-Nahhas. "Peptide Receptor Radionuclide Therapy for Pancreatic Neuroendocrine Tumours." Current Radiopharmaceuticals 12, no. 2 (2019): 126–34. http://dx.doi.org/10.2174/1874471012666190201164132.

Full text

Abstract:

Background: The incidence of pancreatic Neuroendocrine Tumours (pNETs) has increased considerably in the last few decades. The characteristic features of this tumour and the development of new investigative and therapeutic methods had a great impact on its management. Objective: The aim of this review is to investigate the outcome of Peptide Receptor Radionuclide Therapy (PRRT) in the treatment of pancreatic neuroendocrine tumours. Methods: A comprehensive literature search strategy was used based on two databases (SCOPUS, and PubMed). We considered all studies published in English, evaluating

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!